Michael Lee

Mr. Lee is a Co-founder and Portfolio Manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York. He also serves on the Board of Directors of Fate Therapeutics. Prior to Redmile, Mr. Lee worked as a biotechnology investor at Steeple Capital, and before that at Welch Capital Partners and Prudential Equity Group. Mr. Lee holds a B.S. in Molecular and Cellular Biology from the University of Arizona.